Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Aims: High immune cell infiltration in gliomas establishes an immunosuppressive tumor microenvironment, which in turn promotes resistance to immunotherapy. Hence, it is important to identify novel targets associated with high immune cell infiltration in gliomas. Our previous study showed that serum levels of beta-2 microglobulin (B2M) in lower-grade glioma patients were lower than those in glioblastoma patients. In the present study, we focused on exploring the roles of B2M in glioma immune infiltration.

Methods: A large cohort of patients with gliomas from the TCGA, CGGA, and Gravendeel databases was included to explore differential expression patterns and potential roles of B2M in gliomas. A total of 103 glioma tissue samples were collected to determine the distributions of B2M protein levels by immunofluorescent assays. Kaplan-Meier survival analysis and meta-analysis were used for survival analysis. GO(Gene-ontology) enrichment analysis, co-expression analysis, KEGG(Kyoto Encyclopedia of Genes and Genomes) pathway analysis, and immune infiltration analysis were performed to explore roles and related mechanisms of B2M in glioma.

Results: We found that both B2M mRNA and protein levels were abnormally upregulated in glioma samples compared with those from normal brain tissue. B2M expression was correlated with tumor grade and was downregulated in IDH1 mutant samples. Furthermore, B2M was a moderately sensitive indicator for predicting the mesenchymal molecular subtype of gliomas. Interestingly, glioma patients with lower B2M expression had remarkably longer survival times than those with higher B2M expression. Moreover, meta-analysis showed that B2M was an independent predictive marker in glioma patients. The results of GO enrichment analysis revealed that B2M contributed to immune cell infiltration in glioma patients. In addition, results of KEGG pathway analysis and co-expression analysis suggested that B2M may mediate glioma immune infiltration via chemokines.

Conclusions: We conclude that B2M levels are critical for the survival times of glioma patients, at least in part due to mediating high immune infiltration.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265948PMC
http://dx.doi.org/10.1111/cns.13649DOI Listing

Publication Analysis

Top Keywords

glioma patients
24
b2m
14
high immune
12
immune cell
12
cell infiltration
12
immune infiltration
12
b2m expression
12
glioma
10
analysis
9
beta-2 microglobulin
8

Similar Publications

Background: High-grade astrocytoma with piloid features (HGAP) was recently added to the WHO 2021 CNS classification system among the group of circumscribed astrocytic gliomas. These tumors present with high-grade piloid histology with similarities to glioblastoma. HGAPs in the pineal region become particularly challenging due to its deep location and proximity to deep venous structures, the midbrain, and the thalamus.

View Article and Find Full Text PDF

Background: Despite advances in understanding the effective connectivity (EC) of brain networks in leucine-rich glioma-inactivated 1 (LGI1) antibody encephalitis, the specific cause and underlying mechanisms of LGI1 encephalitis remain unclear.

Materials And Methods: The study included 27 patients with anti-LGI1 encephalitis and 28 age- and sex-matched normal controls. Amplitude of low-frequency fluctuation (ALFF) analysis identified altered brain regions.

View Article and Find Full Text PDF

Glioma therapy faces substantial challenges primarily due to the restrictive nature of the blood-brain barrier (BBB), limiting effective drug penetration and reducing therapeutic efficacy. Recent advancements in novel drug delivery systems (DDS), including exosome-mediated carriers, drug conjugates, and ultrasound-assisted delivery, have demonstrated promising results in overcoming these limitations. Exosomes offer superior biocompatibility, efficient BBB crossing, and natural cellular targeting capabilities; drug conjugates enable highly selective drug delivery through tumor-specific ligands; and ultrasound-assisted systems transiently disrupt the BBB to permit greater drug entry.

View Article and Find Full Text PDF

Background: Glioblastoma (GBM) is an extremely aggressive brain tumor, marked by restricted therapeutic possibilities and a generally unfavorable prognosis. GBM's complexity and heterogeneity necessitate comprehensive genetic and immunological profiling to enhance therapeutic strategies.

Methods: The study integrated The Cancer Genome Atlas (TCGA) and Integrative Epidemiology Unit Open Genome-Wide Association Studies (IEU OpenGWAS) data to identify genetic factors influencing GBM using expression quantitative trait loci (eQTL) and genome-wide association studies (GWAS).

View Article and Find Full Text PDF

Background: Disruption of the blood-brain barrier (BBB) in high-grade brain tumors is characterized by contrast accumulation on diagnostic imaging. This window of opportunity study correlates contrast imaging features with the tumor distribution of BBB-permeable (levetiracetam) and -impermeable (cefazolin) drugs.

Methods: Patients with a clinical diagnosis of a high-grade brain tumor underwent MRI for surgical planning.

View Article and Find Full Text PDF